Acumen Pharmaceuticals, Inc. Cash And Cash Equivalents At Carrying Value

• Acumen Pharmaceuticals, Inc. showed an increase of +51.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
• This data is from Acumen Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2020: $3.24 million | Q3 2020: $1.96 million | Q2 2021: $68.81 million | Q3 2021: $135.80 million | Q4 2021: $122.16 million | Q1 2022: $108.76 million | Q2 2022: $111.07 million | Q3 2022: $157.54 million | Q3 2023: $94.92 million | Q1 2024: $46.93 million | Q2 2024: $67.96 million | Q3 2024: $33.18 million | Q1 2025: $30.16 million | Q2 2025: $36.81 million | Q3 2025: $46.83 million.
• Over the full 7 years of available data (2019 to 2025), Acumen Pharmaceuticals, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 724.0%.
• Historical annual values: Fiscal year 2025: $53.99 million | Fiscal year 2024: $35.63 million | Fiscal year 2023: $66.89 million | Fiscal year 2022: $130.10 million | Fiscal year 2021: $122.16 million | Fiscal year 2020: $43.78 million | Fiscal year 2019: $6.55 million.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026